Drug intelligence / Profile preview

Chikungunya virus vaccine (mRNA-1388)

Development stage: Phase 1
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A novel investigational mRNA-based vaccine candidate developed for the prevention of chikungunya virus infection. The vaccine, known as VAL-181388 or mRNA-1388, encodes structural proteins of the chikungunya virus to elicit an immune response and stimulate production of neutralizing antibodies. It is designed as a prophylactic immunostimulant and has been evaluated in phase 1 clinical trials for safety and immunogenicity in healthy adults. The developer is Moderna Therapeutics. As of the latest updates, no further development beyond early-phase clinical trials has been reported.

Other names: chikungunya virus vaccine (mRNA-1388)VAL-181388VAL181388VAL 181388mRNA-1388mRNA1388mRNA 1388

Targets

TLR2 (Toll-like Receptor 2)CHIKV E2/E1 (Chikungunya virus envelope protein)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on Chikungunya virus vaccine (mRNA-1388).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chikungunya virus vaccine (mRNA-1388).

Explore the full profile